{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-009487","form_type":"8-K","ticker":"FNCHQ","cik":"0001733257","company_name":"Finch Therapeutics Group, Inc.","filed_at":"2023-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.347479+00:00","generated_at":"2026-06-17T18:49:43.963069+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Finch Therapeutics Q4 net loss $27M, cash $71M; patent litigation progress, PRISM4 discontinued","bullets":["Net loss Q4 $27.0M vs $19.1M in Q4 2021; FY2022 net loss $114.6M vs $58.2M in prior year.","Cash and equivalents $71.0M at Dec 31, 2022; estimated $43.3M at Feb 28, 2023; cash runway extended into 2025.","Discontinued PRISM4 Phase 3 trial for CP101 in recurrent C. difficile; database locked, no treatment-related SAEs.","Court adopted Finch's claim constructions for 7/8 terms in patent case vs Ferring/Rebiotix; jury trial set May 2024.","Repaid $16.2M debt to Hercules, subleased Hood Park facility, and launched Strain Bank for licensing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-009487","json":"https://secwatch.observer/filing/0000950170-23-009487.json","markdown":"https://secwatch.observer/filing/0000950170-23-009487.md","text":"https://secwatch.observer/filing/0000950170-23-009487.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733257/000095017023009487/0000950170-23-009487-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733257/000095017023009487/fnch-20230323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T18:49:43.963069+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"965193a916618b1490be6dad722f6920eb229e60","claim":"Finch Therapeutics Group, Inc. reported the fourth quarter of 2022 results: net income $27.0 million.","evidence_excerpt":"Finch reported a net loss of $27.0 million for the fourth quarter of 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733257/000095017023009487/0000950170-23-009487-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2022"},{"label":"Net income","value":"$27.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b2e140f2fc8408cdfebf003ef030123ea5a135c8","claim":"Finch Therapeutics Group, Inc. reported the full year of 2022 results: net income $114.6 million.","evidence_excerpt":"Finch reported a net loss of $114.6 million for the full year of 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733257/000095017023009487/0000950170-23-009487-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year of 2022"},{"label":"Net income","value":"$114.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}